|Last Update: 06/17/13 - 4:00 PM EDT|
|YTD Performance: 26.49%|
|Previous Close: $43.21|
|52 Week Range: $32.51 - $48.00|
|Oustanding Shares: 1,583,729,114|
|Market Cap: 68,337,911,269|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||6||5||9||7|
|Growth Rate (Year over Year)||-1.04%||-23.56%||-6.60%||3.14%|
The billionaire's hedge fund bought heavily into this theme in the first quarter.
Today's investment environment has more moving parts than ever.
The objective of investing is to offset future liabilities and manage risk.
It’s the only thing that explains today’s action.
ABBV was upgraded from Equal-weight to Overweight, Morgan Stanley said. $49 price target. Expect higher Humira sales and the company has a solid pipeline.
Plenty of leadership remains in the health care sector and there’s reason to see further potential.
Pickings are slim this month but get prepared for the deluge coming in May.
These recent IPOs offer noteworthy returns.
ABBV was downgraded from Outperform to Market Perform, BMO Capital said. Valuation call, based on a $42 price target.
ABBV was initiated with a Neutral rating, Credit Suisse said. $37 price target. Cross currents imply minimal stock movement from current price.